|
1
|
Hatzimichael E, Dasoula A, Benetatos L,
Syed N, Dranitsaris G, Crook T and Bourantas K: Study of specific
genetic and epigenetic variables in multiple myeloma. Leuk
Lymphoma. 51:2270–2274. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pichiorri F, Suh SS, Ladetto M, Kuehl M,
Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, et
al: MicroRNAs regulate critical genes associated with multiple
myeloma pathogenesis. Proc Natl Acad Sci USA. 105:12885–12890.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Edwin F, Anderson K, Ying C and Patel TB:
Intermolecular interactions of sprouty proteins and their
implications in development and disease. Mol Pharmacol. 76:679–691.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Feng YH, Wu CL, Shiau AL, Lee JC, Chang
JG, Lu PJ, Tung CL, Feng LY, Huang WT and Tsao CJ:
MicroRNA-21-mediated regulation of Sprouty2 protein expression
enhances the cytotoxic effect of 5-fluorouracil and metformin in
colon cancer cells. Int J Mol Med. 29:920–926. 2012.PubMed/NCBI
|
|
5
|
Lao DH, Chandramouli S, Yusoff P, et al: A
Src homology 3-binding sequence on the C terminus of Sprouty2 is
necessary for inhibition of the Ras/ERK pathway downstream of
fibroblast growth factor receptor stimulation. J Biol Chem.
281:29993–30000. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sayed D, Rane S, Lypowy J, He M, Chen IY,
Vashistha H, Yan L, Malhotra A, Vatner D and Abdellatif M:
MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths. Mol
Biol Cell. 19:3272–3282. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Leone E, Morelli E, Di Martino MT, Amodio
N, Foresta U, Gullà A, Rossi M, Neri A, Giordano A, Munshi NC, et
al: Targeting miR-21 inhibits in vitro and in vivo multiple myeloma
cell growth. Clin Cancer Res. 19:2096–2106. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shah AA, Leidinger P, Blin N and Meese E:
miRNA: small molecules as potential novel biomarkers in cancer.
Curr Med Chem. 17:4427–4432. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Terpos E, Morgan G, Dimopoulos MA, et al:
International Myeloma Working Group recommendations for the
treatment of multiple myeloma-related bone disease. J Clin Oncol.
31:2347–2357. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee
DH, Nguyen JT, Barbsin M, Xu NL, Mahuvakar VR, Andersen MR, et al:
Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic
Acids Res. 33:e1792005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schmittgen TD and Livak KJ: Analyzing
real-time PCR data by the comparative C(T) method. Nat Protoc.
3:1101–1108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
International myeloma working group:
Criteria for the classification of monoclonal gammopathies,
multiple myeloma and related disorders: a report of the
International Myeloma Working Group. Br J Haematol. 12l:749–757.
2003.
|
|
13
|
Cavo M, Rajkumar SV, Palumbo A, et al:
International Myeloma Working Group consensus approach to the
treatment of multiple myeloma patients who are candidates for
autologous stem cell transplantation. Blood. 117:6063–6073. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Liu C, Yu J, Yu S, Lavker RM, Cai L, Liu
W, Yang K, He X and Chen S: MicroRNA-21 acts as an oncomir through
multiple targets in human hepatocellular carcinoma. J Hepatol.
53:98–107. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu J, Wu C, Che X, et al: Circulating
microRNAs, miR-21, miR-122 and miR-223, in patients with
hepatocellular carcinoma or chronic hepatitis. Mol Carcinog.
50:136–142. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pichiorri F, Suh SS, Ladetto M, Kuehl M,
Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, et
al: MicroRNAs regulate critical genes associated with multiple
myeloma pathogenesis. Proc Natl Acad Sci USA. 105:12885–12890.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cabrita MA and Christofori G: Sprouty
proteins, masterminds of receptor tyrosine kinase signaling.
Angiogenesis. 11:53–62. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lito P, Mets BD, Kleff S, O’Reilly S,
Maher VM and McCormick JJ: Evidence that sprouty 2 is necessary for
sarcoma formation by H-Ras oncogene-transformed human fibroblasts.
J. Biol Chem. 283:2002–2009. 2008. View Article : Google Scholar
|
|
19
|
Asangani IA, Rasheed SA, Nikolova DA,
Leupold JH, Colburn NH, Post S and Allgayer H: MicroRNA-21(miR-21)
post-transcriptionally downregulates tumor suppressor Pdcd4 and
stimulates invasion, intravasation and metastasis in colorectal
cancer. Oncogene. 27:2128–2136. 2008. View Article : Google Scholar
|
|
20
|
Wang X, Li C, Ju S, et al: Myeloma cell
adhesion to bone marrow stromal cells confers drug resistance by
microRNA-21 up-regulation. Leuk Lymphoma. 52:1991–1998. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Löffler D, Brocke-Heidrich K, Pfeifer G,
Stocsits C, Hackermüller J, Kretzschmar AK, Burger R, Gramatzki M,
Blumert C, Bauer K, et al: Interleukin-6 dependent survival of
multiple myeloma cells involves the Stat3-mediated induction of
microRNA-21 through a highly conserved enhancer. Blood.
110:1330–1333. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu HY, Li KP, Wang XJ, Liu Y, Lu ZG, Dong
RH, Guo HB and Zhang MX: Set9, NF-kappaB and microRNA-21 mediate
berberine-induced apoptosis of human multiple myeloma cells. Acta
Pharmacol Sin. 34:157–166. 2013. View Article : Google Scholar
|
|
23
|
Xiong Q, Zhong Q, Zhang J, Yang M, Li C,
Zheng P, Bi LJ and Ge F: Identification of novel miR-21 target
proteins in multiple myeloma cells by quantitative proteomics. J
Proteome Res. 11:2078–2090. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Feng YH, Wu CL, Tsao CJ, et al:
Deregulated expression of sprouty2 and microRNA-21 in human colon
cancer: Correlation with the clinical stage of the disease. Cancer
Biol Ther. 11:111–121. 2011. View Article : Google Scholar
|
